Summary
The advent of halogenated pyrimidines (bromodeoxyuridine, BrdU; idoxuridine, IdU) and antibodies to recognize them has opened new horizons for the measurement of proliferation in human tumours. These precursors of DNA can be given to patients and a single biopsy can be taken to measure in a flow cytometer both the fraction of labelled cells and their rate of movement through the S phase. From these two parameters the potential doubling time, TPOT, can be calculated. To measure both parameters simultaneously a compromise is made in the time of assessing the labelling index (LI). LI should ideally be assessed after a very short interval, e.g. 0.5–1 h, to avoid the contaminating influence of any cells dividing between injection and biopsy. However, an interval of 4–8 h is considered necessary to assess TS from the relative movement of cells through the S phase. Several techniques exist to correct for cell division if the interval is long. The simplest correction, which only corrects for the division of labelled cells, is most widely used. Downward correction factors of at least 10% are commonly applied, reducing the observed LI values. In this paper we illustrate graphically the dependence of the appropriate correction factor on various cell kinetic parameters. The duration of G2 is the most critical parameter for both the size and direction of any correction factor. The G2 phase has previously been shown to be about three times longer in human tumours than in rodents. If G2+M is as long as 6 h, the main artefact of the intervals between injection and biopsy up to 7 h is that the observed LI is too low because of division of unlabelled G2 cells. A correction of up to 10% is needed but in an upward direction. A nomogram of probable correction factors as a function of sampling interval is provided. We show from flow cytometric data that G2+M may be shorter than 4 h for head and neck tumours. It is recommended that the correction factor established by gating the flow histogram should always be checked against this nomogram, or that no correction factor should be applied. We have used this mathematical approach to re-evaluate two sets of published LI data for rectal and colorectal tumours. We show that the mathematical correction of each data point leads to a 30% increase in the median value, compared to the simple gating procedure. We question whether other of the published series of LI values gained with BrdU or IdU may also substantially underestimate the true LI values, if a simple gating procedure has been used in an attempt to reduce the impact of divided S phase cells.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Begg, A. C. (1989). Derivation of cell kinetic parameters from human tumours after labelling with bromodeoxyuridine. Br Inst Radiol Report 19: 113–119.
Begg, A. C. (1995). The clinical status of Tpot as a predictor? Or why no tempest in the Tpot? Int J Rad Oncol Biol Phys 32: 1539–1541.
Begg, A. C., McNally, N. J., Shrieve, D. C. & Kärcher, H. (1985). A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6: 620–626.
Begg, A. C., Moonen, L., Hofland, I., Dessing, M. & Bartelink, H. (1988). Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol 11: 337–347.
Begg, A. C., Haustermans, K., Hart, A. A. M., Dische, S., Saunders, M., Zackrisson, B., Gustafsson, H., Coucke, P., Paschoud, N., Hoyer, M., Overgaard, J., Antognoni, P., Richetti, A., Bourhis, J., Bartelink, H., Horiot, J. C., Corvo, R., Giaretti, W., Awwad, H., Shouman, T., Jouffroy, T., Maciorowski, Z., Dobrowsky, W., Struikmans, H. & Wilson, G. D. (1999). The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol (in press.)
Bergström, C., Palmqvist, R., Denekamp, J., Öberg, Å, Tavelin, B. & Stenling, R. (1998). Factors influencing the estimates of proliferative labelling indices in rectal cancer. Radiother Oncol 46: 169–177.
Bennett, M. H., Wilson, G. D., Dische, S., Saunders, M. I., Martindale, C. A., Robinson, B. M., O’Halloran, A. E., Leslie, M. D. & Laing, J. H. E. (1992). Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 65: 870–878.
Brons, P. P. T., Raemaekers, J. M. M., Bogman, MJJT, Van, ERPPEJ, Boezeman, J. B. M., Pennings, A. H. M., Wessels, H. M. C. & Haanen, C. (1992). Cell cycle kinetics in malignant lymphoma studied with in vivo iododeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry. Blood 80: 2336–2343.
Dolbeare, F. A., Grazner, H. G., Pallavicini, M. G. & Gray, J. W. (1983). Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 80: 5573–5577.
Fowler, J. F. & Lindstrom, M. J. (1992). Loss of local control with prolongation in radiotherapy. Int J Rad Oncol Biol Phys 23: 457–467.
Grazner, H. G. (1982). Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218: 474–475.
Howard, A. & Pelc, S. R. (1953). Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity (Edinnburgh) 6: 261–273.
Johansson, M. C., Johansson, R., Baldetorp, B. & Oredsson, S. M. (1998). Comparison of different labelling index formulae used on bromodeoxyuridine flow cytometry data. Cytometry 32: 233–240.
Palmqvist, R., Öberg, Å, Bergström, C., Rutegård, J. N., Zackrisson, B. & Stenling, R. (1998). Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer 77: 917–925.
Rew, D. A., Wilson, G. D., Taylor, I. & Weaver, P. C. (1991). Proliferation characteristics of human colorectal carcinomas measured in vivo. Br J Surg 78: 60–66.
Steel, G. G. (1977). Growth Kinetics of Tumours. Oxford University Press: London.
Terry, N. H. A., Meistrich, M. L., Roubein, L. D., Lynch, P. M., Dubrow, R. A. & Rich, T. A. (1995). Cellular kinetics in rectal cancer. Br J Cancer 72: 435–441.
Terry, N. H. A. & Peters, L. J. (1995). The predictive value of tumour-cell kinetic parameters in radiotherapy. Considerations regarding data production and analysis. J Clin Oncol 13: 1833–1836.
White, R. A., Terry, N. H. A. & Meistrich, M. L. (1990). New methods for calculating kinetic properties of cells in vitro using pulse labelling with bromodeoxyuridine. Cell Tissue Kinet 23: 561–573.
Wilson, G. D., McNally, N. J., Dische, S., Saunders, M. I., Des Rochers, C., Lewis, A. A. & Bennett, M. H. (1988). Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 58: 423–431.
Wilson, G. D. (1993). Limitations of the bromodeoxyuridine technique for measurement of tumour proliferation. In Medical Radiology, Current Topics in Clinical Radiobiology of Tumours, Beck-Bornholdt HP (ed), pp. 27–43. Springer–Verlag: Berlin.
Wilson, M. S., West, C. M. L., Wilson, G. D., Roberts, S. A., James, R. D. & Schofield, P. F. (1993). An assessment of the reliability and reproducibility of measurement of potential doubling times (Tpot) in human colorectal cancers. Br J Cancer 67: 754–759.
Wilson, M. S., West, C. M. L., Wilson, G. D., Roberts, S. A., James, R. D. & Schofield, P. F. (1993). Intra-tumoural heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. Br J Cancer 68: 501–506.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Bergström, C., Begg, A., Palmqvist, R. et al. Labelling indices in human tumours: to apply corrections or not – that is the question. Br J Cancer 80, 1635–1643 (1999). https://doi.org/10.1038/sj.bjc.6690574
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690574